Clinical Trials Directory

Trials / Terminated

TerminatedNCT00004050

Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer

Phase II Study Evaluating the Safety and Efficacy of Neoadjuvant Leuvectin Immunotherapy for the Treatment of Prostate Cancer

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
13 (actual)
Sponsor
Vical · Industry
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Inserting the gene for interleukin-2 into a person's cancer cells may improve the body's ability to fight cancer. Using Leuvectin to deliver this gene may be an effective treatment for prostate cancer. PURPOSE: Phase II trial to study the effectiveness of Leuvectin followed by surgery in treating patients who have stage II or stage III prostate cancer.

Detailed description

OBJECTIVES: * Assess the toxicity and tolerability of neoadjuvant Leuvectin in patients with stage II or III prostate cancer. * Evaluate the efficacy of this regimen in preventing or delaying manifestations of disease progression as demonstrated by biochemical failure or clinical recurrence in this patient population. OUTLINE: This is a multicenter study. Patients receive Leuvectin intraprostatically over 10-30 seconds under ultrasound guidance on day 0 followed by a second injection between days 4 and 7. Between days 8 and 14, patients undergo retropubic prostatectomy. All patients are followed at 2 months. Patients with a PSA no greater than 0.2 ng/mL are followed at 4 months and 6 months, every 3 months for 12 months, and then every 6 months for 3.5 years in the absence of disease progression or biochemical failure. ACTUAL ACCRUAL: 13 patients were accrued for this study.

Conditions

Interventions

TypeNameDescription
BIOLOGICALLeuvectinLeuvectin injected intratumorally followed by prostatectomy

Timeline

Start date
1999-06-01
Primary completion
2003-04-01
Completion
2003-04-01
First posted
2003-10-29
Last updated
2014-07-29

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00004050. Inclusion in this directory is not an endorsement.